Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Augmenting the Team, Scott C. Durbin, New CFO, Aastrom Biosciences (ASTM)

Scott C. Durbin has joined ASTM as Chief Financial Officer (NASDAQ:CFO) and brings more than 15 years of healthcare-related banking, financial and corporate development experience.

Mr. Durbin was formerly COO and CFO of Prescient Medical, which develops diagnostic and therapeutic catheter-based medical devices for the treatment of severe coronary artery disease. While at Prescient, Mr. Durbin raised more than $60 M in private equity financing and helped advance the company through early-stage research, development and regulatory approval. Previously he served as a finance and corporate development consultant for Scios (a Johnson & Johnson subsidiary), and Alteon. Prior to this consulting work, he was an investment banker with Lehman Brothers, where he completed more than $5 B in financings and M&A transactions for life science companies. Mr. Durbin earned an MPH in health management from the Yale University School of Medicine & School of Management and a BS from the University of Michigan.

“I’m very pleased to welcome Scott to the leadership team at Aastrom. Scott has an exceptionally strong track record in finance, corporate strategy and operations in the life sciences sector,” said Tim Mayleben, President and CEO of Aastrom. “His industry expertise will be a key asset to Aastrom as we continue to advance our therapies through late stages of clinical development.”